Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model

被引:52
作者
Hill, R
Song, YR
Cardiff, RD
Van Dyke, T [1 ]
机构
[1] Univ N Carolina, Dept Genet, Chapel Hill, NC 27514 USA
[2] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA
关键词
D O I
10.1158/0008-5472.CAN-05-1579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because each change in the evolution of a cancer is predicated on the effects of previous events, a full understanding of selective changes and their effect on tumor progression can only be understood in the context of appropriate initiating events. Here, we define the effect of pRb function inactivation in prostate epithelium on both the initiation of prostate cancer and the establishment of selective pressures that lead to diminished Pten function and tumor evolution. Using genetically engineered mice, we show that inactivation of the pRb family proteins (Rb/p107/p130) induces epithelial proliferation and apoptosis and is sufficient to produce prostatic intraepithelial neoplasia (PIN) lesions. Over time, adenocarcinomas develop in all mice with no evidence of neuroendocrine tumors. Apoptosis is dependent on Pten function and not p53, unlike other epithelial cell types tested previously. Consequently, Pten hemizygosity reduces apoptosis by 50%, accelerating progression to adenocarcinomas with heterogeneous composition. Heterogeneity is associated with concurrent Pten haploinsufficiency and focal selective progression to complete Pten loss, which yields distinct tumor properties. Given that this analysis models the apparent timing of highly penetrant events in human prostate cancer, observed effects may recapitulate the natural evolution of prostate cancer development.
引用
收藏
页码:10243 / 10254
页数:12
相关论文
共 51 条
  • [1] Molecular genetics of prostate cancer
    Abate-Shen, C
    Shen, MM
    [J]. GENES & DEVELOPMENT, 2000, 14 (19) : 2410 - 2434
  • [2] ARE NEUROENDOCRINE CELLS OF PRACTICAL VALUE AS AN INDEPENDENT PROGNOSTIC PARAMETER IN PROSTATE-CANCER
    ALLEN, FJ
    VANVELDEN, DJJ
    HEYNS, CF
    [J]. BRITISH JOURNAL OF UROLOGY, 1995, 75 (06): : 751 - 754
  • [3] BOOKSTEIN R, 1993, CANCER RES, V53, P3369
  • [4] Bostwick DG, 1996, PROSTATE, V29, P117
  • [5] BRAWER MK, 1985, CANCER RES, V45, P3663
  • [6] ALLELIC LOSS OF THE RETINOBLASTOMA GENE IN PRIMARY HUMAN PROSTATIC ADENOCARCINOMAS
    BROOKS, JD
    BOVA, GS
    ISAACS, WB
    [J]. PROSTATE, 1995, 26 (01) : 35 - 39
  • [7] CHEN JD, 1992, ONCOGENE, V7, P1167
  • [8] Claudio PP, 2002, CLIN CANCER RES, V8, P1808
  • [9] Cooney KA, 1996, CANCER RES, V56, P1142
  • [10] Dawkins HJS, 2000, PROSTATE, V44, P265